The
global lymphopenia therapeutics market size is poised to grow by USD 392.51 million during 2019-2023,
according to a new report by Technavio, progressing at a CAGR of close to 4%
during the forecast period.
Read the 155-page research report with TOC on "Lymphopenia
Therapeutics Market Analysis Report by product (acquired lymphopenia and
inherited lymphopenia) and geography (North America, Europe, Asia, and ROW)
2019 - 2023" at
The market is driven by the increasing risk factors for lymphopenia.
Also, the growing initiatives from government agencies and rising awareness
about the underlying causes of lymphopenia are anticipated to boost the growth
of the lymphopenia therapeutics market.
Increasing incidence of risk factors including infectious diseases,
autoimmune diseases, inherited diseases, or other blood diseases is leading to
rising cases of lymphopenia. Highly prevalent contagious diseases including
hepatitis and tuberculosis are increasing the risk of lymphocytopenia, which in
turn, will lead to a surge in lymphopenia cases. Furthermore, autoimmune
diseases, including lupus, rheumatoid arthritis, and other chronic conditions
are also contributing to the growing incidence of lymphopenia. This has led
various government and non-government organizations to conduct awareness
programs. These initiatives towards increasing awareness about the several risk
factors of lymphopenia will contribute to the lymphopenia therapeutics market
growth during the forecast period.
Major Five Lymphopenia Therapeutics Companies:
Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co. is involved in the discovery, development,
licensing, manufacturing, marketing, distribution, and sale of innovative
medicines. In December 2018, the company collaborated with Vedanta Biosciences
Inc., to announce a clinical trial for evaluating OPDIVO in combination VE800
in patients with advanced cancers. The company offers SUSTIVA and DAKLINZA to
treat chronic hepatitis C.
CSL Ltd.
CSL Ltd. operates in key business segments, including CSL Behring and
Seqirus. The company’s key offerings for the lymphopenia therapeutics market
including Hizentra and Privigen. It launched the US FDA approved Privigen for
the treatment of adults suffering from chronic inflammatory demyelinating
polyneuropathy for improving neuromuscular disabilities.
Gilead Sciences Inc.
Gilead Sciences Inc. offers a wide range of products, including
BIKTARVY, STRIBILD, GENVOYA, ATRIPLA, TRUVADA, DESCOVY, HARVONI, and SOVALDI.
The company has also collaborated with healthcare industry participants
including Galapagos NV, Carna Biosciences Inc. and Renown Institute for Health
Innovation to introduce innovative drug discovery platforms.
GlaxoSmithKline Plc
GlaxoSmithKline Plc operates in key business segments, including
pharmaceuticals, vaccines, and consumer healthcare. The company offers a wide
range of products including BENLYSTA, RETROVIR, DOVATO, TRIUMEQ, TIVICAY, and
COMBIVIR. Also, in August 2019, the company completed its transaction with
Pfizer to combine its consumer healthcare businesses into a world-leading joint
venture.
Grifols SA
Grifols SA operates in key business segments, including bioscience,
diagnostic, hospital, bio supplies, and others. The company mainly offers
GAMUNEX-C and Flebogamma for the treatment of primary humoral immunodeficiency
and idiopathic thrombocytopenic purpura. Furthermore, in July 2019, the company
received the US FDA approval for XEMBIFY to treat primary immunodeficiencies.
No comments:
Post a Comment